trilaciclib
Ligand Summary
Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.
UNII: U6072DO9XG
PubChem: 68029831
Guide to Pharmacology: 9626
ChEMBL: CHEMBL3894860
DrugCentral: 5442
LyCHI: XDU2WJ5CMMNN
Target Activities
12 Activities
Items per page:
10
1 – 10 of 12
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | ||||||
Kd | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | INHIBITOR | |||||
IC50 | INHIBITOR | |||||